Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 17 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 11832
Sealed predictions
- VAV3 in dopamine neurons, braak+0.75 (p 0.020) → +0.22 (p 0.576)receipt 11840
Swarm cases
receipt 11840: VAV3 in dopamine neurons, braak
- power
- full sample +0.48 (p 0.045, n 18), 95% CI +0.01 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.51 (p 0.031, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.44 (p 0.067, n 18). could be the mix.
- skeptic
- leave-one-out range +0.40 to +0.69, sign flips 0; without severely affected donors +0.48 (p 0.045, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VAV3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts